1 recruiting. 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Recruiting 1 |
Follow Disorders, Lymphoproliferative: new trials by email Literature Review of Disorders, Lymphoproliferative trials Research Report on Disorders, Lymphoproliferative
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders and EBV-Positive Non-HodgkinLymphomas Nivolumab - Epstein-Barr Virus Infections, Lymphoma | Phase 2 | Recruiting | National Cancer Institute (NCI) | 40 | 2018-04-26 | 2026-10-16 |
Epstein-Barr Virus Infections (1) · Lymphoma (1) · Lymphoproliferative Disorders (1)
DNA Virus Infections (1) · Hemic and Lymphatic Diseases (1) · Herpesviridae Infections (1) · Immune System Diseases (1) · Immunoproliferative Disorders (1) · Infections (1) · Lymphatic Diseases (1) · Neoplasms (1) · Neoplasms by Histologic Type (1) · Tumor Virus Infections (1) · Virus Diseases (1)
Nivolumab (1)
National Cancer Institute (NCI) (1)
United States (1)